Adalimumab is a biologic agent that can be used to treat moderate-to-severe plaque psoriasis in adults.
Adalimumab is a TNF-α antagonist that targets and blocks T-lymphocyte activity and the release of specific cytokines for the treatment of psoriasis, especially in patients with moderate-to-severe plaque psoriasis who have failed to respond to treatment with conventional medications.
Contraindications are active tuberculosis, sepsis, opportunistic infections, moderate-to-severe heart failure, hypersensitivity to adalimumab or ingredients in the preparation, and possible adverse reactions include infection, injection site reactions, headache, and muscle pain. Before using adalimumab a complete medical examination is also carried out, focusing on the presence of active tuberculosis, malignant tumors, autoimmune diseases, cardiac diseases.
If you suffer from psoriasis, it is recommended that you visit a hospital in time to have a professional physician formulate a suitable treatment plan for you and assess whether you are suitable for using adalimumab, and do not use the drug on your own.